Source link : https://www.newshealth.biz/health-news/fda-expands-approval-of-treatment-for-gpp/
The US Food and Drug Administration (FDA) has approved spesolimab-sbzo, an interleukin (IL)-36 receptor antagonist, for the treatment of generalized pustular psoriasis (GPP) in adults and in pediatric patients aged ≥ 12 years who weigh ≥ 40 kg, according to an announcement from the manufacturer. This is an expanded indication for spesolimab-sbzo, first approved in […]
Author : News Health
Publish date : 2024-03-20 11:14:09
Copyright for syndicated content belongs to the linked Source.